The ARG1 Knockout 769-P Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the 769-P human renal cell carcinoma line, engineered to disrupt the ARG1 gene. This polyclonal format yields a heterogeneous cell pool, avoiding clonal selection biases and enabling robust population-level functional analyses and multi-parametric studies.
The 769-P cell line originates from a primary clear cell renal cell carcinoma and serves as a widely used model for kidney cancer research. It retains hallmark features such as VHL pathway inactivation and HIF stabilization, providing a relevant tumor microenvironment for studying arginine metabolism and immune evasion.
ARG1 encodes arginase 1, which hydrolyzes arginine to ornithine and urea, a critical step in the urea cycle and a regulatory node in extrahepatic tissues. ARG1 is transcriptionally activated by STAT6 downstream of IL-4 and IL-13, with contributions from C/EBP??, PPARG, TGF-??, and HIF1A. By depleting arginine, ARG1 competes with NOS2, limiting nitric oxide production, while the ornithine product fuels ODC1-mediated polyamine synthesis and OAT-driven proline metabolism. Thus, ARG1 intersects nitrogen metabolism, immune signaling, and cell proliferation through its effects on NOS2, ODC1, and OAT.
In 769-P RCC cells, ARG1 knockout is predicted to reprogram arginine metabolism by reducing ornithine and polyamine synthesis while increasing arginine availability for NOS2-mediated NO production. This metabolic shift may impair tumor proliferation, sensitize cells to arginine deprivation, and disrupt immunosuppressive mechanisms. Given the role of ARG1 in immune evasion in clear cell RCC, this knockout model enables dissection of tumor-intrinsic metabolic vulnerabilities and the interplay between arginine metabolism and immune checkpoint pathways.
This polyclonal knockout model is suitable for immuno-oncology and tumor metabolism research. Key applications include co-culture T-cell killing assays, metabolomic profiling by LC-MS, and nitric oxide quantification via Griess assay, alongside standard biochemical validation by Western blot and arginase activity assays. These tools enable investigation of arginine deprivation therapy, immunosuppression, and the molecular links between ARG1 and immune checkpoint regulation. For further information, please contact Ascent Research.
